{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:08Z","timestamp":1787017028113,"version":"build-2736575974"},"reference-count":53,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Chinese National Natural Science Foundation","doi-asserted-by":"crossref","award":["81772476"],"award-info":[{"award-number":["81772476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,17]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacy and safety of different platinum adjuvant chemotherapy regimens for early-stage resected non-small-cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review with network meta-analysis of randomised trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, EMBASE, The Cochrane Library, Web of Science and Scopus Google Scholar were searched through 12 March 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Eligible randomised controlled trials (RCTs) comparing the postoperative platinum chemotherapy regimen with the observation-controlled group or comparing two platinum chemotherapy regimens head-to-head were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>The primary outcome was the efficacy of adjuvant chemotherapy regimens including relapse-free survival (RFS), overall survival (OS), 2-year, 3-year, 5-year RFS rate and OS rate. The secondary outcome was the rate of grade 3\u20134 toxicity assessments. Cochrane Handbook (V.5) was used for the risk of bias assessment. Analyses were performed using R software V.4.3.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>20 RCTs with a sample size of 5483 were enrolled in meta-analysis. The chemotherapy group had a significant RFS and OS advantage compared with the observation group (HR 0.67; 95% CI 0.56 to 0.81, p&lt;0.0001; HR 0.80; 95%\u2009CI, 0.73 to 0.88, p&lt;0.0001, respectively). Compared with the observation arm, only the \u2018cisplatin_vinorelbine\u2019 regimen had a significant RFS and OS advantage (HR 0.63; 95%\u2009CI 0.43 to 0.87; HR 0.74; 95%\u2009CI 0.63 to 0.87, respectively) while the remaining chemotherapy regimens had no significant difference of efficacy compared with the observation group. In terms of the safety of adjuvant chemotherapy, the incidence of haematological toxicities and nausea\/vomiting was not significantly higher in the \u2018cisplatin_vinorelbine\u2019 arm than in other chemotherapy group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study summarised the adjuvant cytotoxicity chemotherapy regimens for patients with early-stage resected NSCLC. Our analysis may provide some guiding significance for the clinicians when determining the optimal chemotherapy regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057098","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:34:33Z","timestamp":1655120073000},"page":"e057098","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-8117","authenticated-orcid":false,"given":"Lan-Lan","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Di","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lv","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael Abdullah-Sultan","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"2025120519093965000_12.6.e057098.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025120519093965000_12.6.e057098.2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"2025120519093965000_12.6.e057098.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.6.1710"},{"key":"2025120519093965000_12.6.e057098.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"2025120519093965000_12.6.e057098.5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(01)00376-2","article-title":"The role of chemotherapy in early non-small-cell lung cancer management","volume":"34","author":"Rosell","year":"2001","journal-title":"Lung Cancer"},{"key":"2025120519093965000_12.6.e057098.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"2025120519093965000_12.6.e057098.7","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.0768503"},{"key":"2025120519093965000_12.6.e057098.8","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181c814e7"},{"key":"2025120519093965000_12.6.e057098.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"2025120519093965000_12.6.e057098.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4855"},{"key":"2025120519093965000_12.6.e057098.11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.12669\/pjms.315.7380","article-title":"Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer","volume":"31","author":"Chen","year":"2015","journal-title":"Pak J Med Sci"},{"key":"2025120519093965000_12.6.e057098.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds578"},{"key":"2025120519093965000_12.6.e057098.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"2025120519093965000_12.6.e057098.14","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025120519093965000_12.6.e057098.15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk196"},{"key":"2025120519093965000_12.6.e057098.16","doi-asserted-by":"crossref","first-page":"v72","DOI":"10.1093\/annonc\/mdj955","article-title":"Chemotherapy of advanced NSCLC in special patient population","volume":"17 Suppl 5","author":"Gridelli","year":"2006","journal-title":"Ann Oncol"},{"key":"2025120519093965000_12.6.e057098.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1816"},{"key":"2025120519093965000_12.6.e057098.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.8918"},{"key":"2025120519093965000_12.6.e057098.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30729-5"},{"key":"2025120519093965000_12.6.e057098.20","unstructured":"Higgins JPT . Cochrane Handbook for systematic reviews of interventions. Cochrane collaboration. 10, 2011."},{"key":"2025120519093965000_12.6.e057098.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"2025120519093965000_12.6.e057098.22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00280-020-04104-1","article-title":"A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido lung cancer clinical study Group trial (HOT0703)","volume":"86","author":"Fukumoto","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025120519093965000_12.6.e057098.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.08.028"},{"key":"2025120519093965000_12.6.e057098.24","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1200\/JCO.19.02674","article-title":"Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA Nonsquamous non-small-cell lung cancer","volume":"38","author":"Kenmotsu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025120519093965000_12.6.e057098.25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0022-5223(19)33714-6","article-title":"Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer. Results of a randomized prospective study. The Japan clinical Oncology Group","volume":"106","author":"Ohta","year":"1993","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025120519093965000_12.6.e057098.26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2019.11.009","article-title":"Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503","volume":"141","author":"Kubota","year":"2020","journal-title":"Lung Cancer"},{"key":"2025120519093965000_12.6.e057098.27","doi-asserted-by":"crossref","first-page":"79703","DOI":"10.18632\/oncotarget.19114","article-title":"Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"2025120519093965000_12.6.e057098.28","doi-asserted-by":"crossref","first-page":"S642","DOI":"10.1016\/j.jtho.2016.11.831","article-title":"P1.05-046 Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years\u2019 Median Follow-Up","volume":"12","author":"Zhong","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"2025120519093965000_12.6.e057098.29","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.7314\/APJCP.2012.13.9.4505","article-title":"Post-Operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients","volume":"13","author":"Wang","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"2025120519093965000_12.6.e057098.30","unstructured":"YY-zhuo et.al . Recombinant human endostatin combined with TP regimen as postoperative adjuvant treatment for non-small-cell lung cancer. Med J Chin PLA 2012;37."},{"key":"2025120519093965000_12.6.e057098.31","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivv050"},{"key":"2025120519093965000_12.6.e057098.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-9006"},{"key":"2025120519093965000_12.6.e057098.33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jtho.2015.09.014","article-title":"Three-Year follow-up of a randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine (the treat study)","volume":"11","author":"Kreuter","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025120519093965000_12.6.e057098.34","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21933"},{"key":"2025120519093965000_12.6.e057098.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043623"},{"key":"2025120519093965000_12.6.e057098.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2004.03.041"},{"key":"2025120519093965000_12.6.e057098.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70804-X"},{"key":"2025120519093965000_12.6.e057098.38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.lungcan.2015.11.007","article-title":"A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage Ib or II non-small-cell lung cancer","volume":"90","author":"Schmid-Bindert","year":"2015","journal-title":"Lung Cancer"},{"key":"2025120519093965000_12.6.e057098.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.6204"},{"key":"2025120519093965000_12.6.e057098.40","unstructured":"A randomized controlled study of postoperative adjuvant chemoimmunotherapy of resected non-small cell lung cancer with IL2 and LAK cells: H.Kimura, Y.Yamaguchi, T.Fujisawa, M.Baba, and M.Shiba Institute of Pulmonary Cancer Research, School of Medicine, Chi %J Lung Cancer 1991."},{"key":"2025120519093965000_12.6.e057098.41","doi-asserted-by":"crossref","DOI":"10.1097\/01.JTO.0000283860.47170.b3","article-title":"P2-202: postoperative adjuvant therapy for stage IIIA non small cell lung cancer","volume":"2","author":"Park","year":"2007","journal-title":"Journal of Thoracic Oncology"},{"key":"2025120519093965000_12.6.e057098.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2005.01.039"},{"key":"2025120519093965000_12.6.e057098.43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg059"},{"key":"2025120519093965000_12.6.e057098.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7010.899"},{"key":"2025120519093965000_12.6.e057098.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60059-1"},{"key":"2025120519093965000_12.6.e057098.46","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","article-title":"Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial","volume":"18","author":"Wakelee","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025120519093965000_12.6.e057098.47","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0232"},{"key":"2025120519093965000_12.6.e057098.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214271"},{"key":"2025120519093965000_12.6.e057098.49","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181d89f95"},{"key":"2025120519093965000_12.6.e057098.50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr033"},{"key":"2025120519093965000_12.6.e057098.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.11.015"},{"key":"2025120519093965000_12.6.e057098.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.11.009"},{"key":"2025120519093965000_12.6.e057098.53","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1517\/17425255.2013.804065","article-title":"An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment","volume":"9","author":"Caffo","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:09:54Z","timestamp":1764990594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-057098"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057098","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}